Barriers to Timely Diagnosis of Interstitial Lung Disease Barriers to Timely Diagnosis of Interstitial Lung Disease
What are the barriers patients with interstitial lung diseases may face in obtaining a timely and accurate diagnosis?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. (Source: World Pharma News)
Source: World Pharma News - March 19, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
Lung Disease Common in Late-Onset SLE (CME/CE)
(MedPage Today) -- Rates of interstitial lung disease more than doubled (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2018 Category: Primary Care Source Type: news
Medical News Today: What to know about interstitial lung disease
A look at interstitial lung disease, a group of diseases that make it difficult to get enough oxygen. Included is detail on types and complications. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 18, 2018 Category: Consumer Health News Tags: Pulmonary System Source Type: news
Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease.
The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported.
Get the full story at out sister site, Drug Delivery Business News.
The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news
Pirfenidone Promising for RA - Linked Interstitial Lung Disease
Phase 2 trial terminated early, underpowered to meet primary end point, but limited results suggest pirfenidone may slow progression of RA - ILD (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news
Risk Score Developed for RA - Linked Interstitial Lung Disease
Independent risk factors for rheumatoid arthritis (RA) - associated ILD include MUC5B rs35705950 T risk allele, male sex, older age at RA onset (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Pulmonology, Rheumatology, Journal, Source Type: news
Exercise Training in Interstitial Lung Disease Exercise Training in Interstitial Lung Disease
Pulmonary rehabilitation programs including exercise training may be an effective intervention in stable patients with interstitial lung disease.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Warning of too few specialist nurses for incurable lung disease
A lack of access to specialist nurses is an important factor contributing to a crisis in care for patients with interstitial lung disease (ILD), according to a charity report. (Source: Nursing Times)
Source: Nursing Times - September 18, 2017 Category: Nursing Source Type: news
Interstitial Pneumonitis (Interstitial Lung Disease)
Title: Interstitial Pneumonitis (Interstitial Lung Disease)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 8, 2017 Category: Respiratory Medicine Source Type: news
Occupational Exposures Linked to Interstitial Lung Disease
Job exposure matrix score increase in vapors, gas, dust, fumes exposure ups high attenuation areas (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 7, 2017 Category: Respiratory Medicine Tags: Pulmonology, Journal, Source Type: news
FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news
Interstitial Lung Disease Boosts Mortality in RA (CME/CE)
(MedPage Today) -- New study highlights need for early diagnosis, better treatments (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - June 27, 2017 Category: Respiratory Medicine Source Type: news
National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news
National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news
